Cyprotex Ltd-医療機器分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013865)
◆英語タイトル:Cyprotex Ltd - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013865
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:31
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Cyprotex Ltd (Cyprotex), a subsidiary of Evotec AG is a provider of ADME-Tox contract research services. It provides these services to the biotechnology, pharmaceutical, cosmetics/personal care and chemical industries. The company’s core capabilities include high quality mechanistic toxicology, in vitro ADME screening services, and high content toxicology screening services, including proprietary CellCiphr toxicity prediction technology, predictive modelling using QSAR and PBPK techniques, including Cloe PK for in vivo PK prediction, and a range of endocrine and skin, ocular disruption services. Cyprotex partners with various organizations within the cosmetics and personal care industry, biotech and pharmaceutical industry, and the chemical industry. The company’s operations are primarily carried out in the UK and the US. Cyprotex is headquartered in Nether Alderley, Cheshire, the UK.

Cyprotex Ltd – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cyprotex Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Cyprotex Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Cyprotex Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Cyprotex Ltd, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Cyprotex Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Cyprotex Ltd, Medical Equipment, Deal Details 10
Partnerships 10
Cyprotex Enters Into Agreement With InSphero For New 3D Microtissue Service 10
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 11
Acquisition 12
Evotec Acquires Cyprotex for USD68 Million 12
Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To US$6 Million 14
Cyprotex Ltd – Key Competitors 15
Cyprotex Ltd – Key Employees 16
Cyprotex Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
Jan 26, 2017: Cyprotex, an Evotec Company, Expands into New UK Facility at Alderley Park 18
Financial Announcements 19
Aug 02, 2016: Cyprotex: Interim Results 2016 19
Apr 01, 2016: Cyprotex Announces Final results for the year ended 31 December 2015 22
Corporate Communications 23
Sep 26, 2016: Cyprotex: Cyprotex appoint new Director of US Operations 23
Sep 26, 2016: Cyprotex appoint new Director of US Operations 24
Product News 25
Nov 29, 2016: Cyprotex: Launch of in vitro h-CLAT Service for assessing skin sensitisation 25
Oct 06, 2016: Cyprotex: New DDI-Fusion Combines Chemical Structure with In Vitro Data to Predict Human Drug-Drug Interactions 26
Jul 07, 2016: Cyprotex Announces Launch of New Advanced 3D Cardiotoxicity Model 27
Jun 23, 2016: Cyprotex Launch New Endocrine Disruption Service 28
Other Significant Developments 29
Jun 09, 2016: Cyprotex Purchase New IntelliCyt iQue Screener for Expansion of Cell-Based Services 29
Apr 26, 2016: Launch of GLP-Compliant Genotoxicity Services 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Cyprotex Ltd, Medical Equipment, Key Facts, 2016 2
Cyprotex Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Cyprotex Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Cyprotex Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Cyprotex Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Cyprotex Ltd, Deals By Market, 2011 to YTD 2017 8
Cyprotex Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Cyprotex Enters Into Agreement With InSphero For New 3D Microtissue Service 10
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 11
Evotec Acquires Cyprotex for USD68 Million 12
Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To US$6 Million 14
Cyprotex Ltd, Key Competitors 15
Cyprotex Ltd, Key Employees 16
Cyprotex Ltd, Subsidiaries 17

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Cyprotex Ltd-医療機器分野:企業M&A・提携分析(Cyprotex Ltd - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆